Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 6/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16680694 | 1.00 | APLNR (0.43) | APLNRCFDKMOFFAR1MAPK1 | |
| SCHEMBL16680800 | 0.77 | ALDH1A1 (0.47) | FFAR1CTSAEEF2KHPGD | |
| SCHEMBL16680798 | 0.77 | ALDH1A1 (0.47) | FFAR1CTSAEEF2KHPGD | |
| SCHEMBL4023097 | 0.77 | APLNR (0.35) | APLNRKMOCTSAEEF2KNR1I2 | |
| SCHEMBL3947856 | 0.72 | APLNR (0.39) | APLNRMAPK1FFAR2AGBL2NR1I2 | |
| SCHEMBL17765226 | 0.72 | APLNR (0.51) | APLNRKMOMAPK1FFAR2AGBL2 | |
| SCHEMBL1927308 | 0.71 | NR1I2 (0.48) | APLNRMAPK1FFAR2NR1I2 | |
| SCHEMBL420311 | 0.71 | NR1I2 (0.48) | APLNRMAPK1FFAR2NR1I2 | |
| SCHEMBL1693620 | 0.71 | NR1I2 (0.48) | APLNRMAPK1FFAR2NR1I2 | |
| SCHEMBL19729243 | 0.71 | CTSA (0.31) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452990-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| EP-2864322-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126492-A1 | Complement Pathway Modulators and Uses Thereof | CFB, CFH, TFPI | APLNR 275/4885CFD 4/4885KMO 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.